Ricordare il futuro - Universita' degli Studi "Magna Graecia"

562. Stosic-Grujicic, S; Cvetkovic, I; Mangano, K; Fresta, M; Maksimovic-Ivanic, D; Harhaji, L;
Popadic, D; Momcilovic, M; Miljkovic, D; Kim, J; Al Abed, Y; Nicoletti, F. A potent immunomodulatory
compound, (S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid, prevents spontaneous and accelerated
forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by
multiple low doses of streptozotocin in CBA/H mice. JOURNAL OF PHARMACOLOGY AND
EXPERIMENTAL THERAPEUTICS, 320 (3): 1038-1049 MAR 2007
563. Striano, P; Lispi, ML; Gennaro, E; Madia, F; Traverso, M; Bordo, L; Aridon, P; Boneschi, FM;
Barone, B; dalla Bernardina, B; Bianchi, A; Capovilla, G; De Marco, P; Dulac, O; Gaggero, R;
Gambardella, A; Nabbout, R; Prud'homme, JF; Day, R; Vanadia, F; Vecchi, M; Veggiotti, P; Vigevano, F;
Viri, M; Minetti, C; Zara, F. Linkage analysis and disease models in benign familial infantile seizures: A
study of 16 families. EPILEPSIA, 47 (6): 1029-1034 JUN 2006
564. Tafi, A; Agamennone, M; Tortorella, P; Alcaro, S; Gallina, C; Botta, M. AMBER force field
implementation of the boronate function to simulate the inhibition of beta-lactamases by alkyl and aryl
boronic acids. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 40 (11): 1134-1142 NOV 2005
565. Tagliaferri, P; Tassone, P; Pietragalla, A; Rotundo, MS; Barbieri, V; Budillon, A; Caraglia, M;
Costanzo, FS; Venuta, S. Molecular rationales for signal transduction therapy and chemoprevention of
BRCA1-related breast and ovarian tumours. CURRENT SIGNAL TRANSDUCTION THERAPY, 2 (2):
165-173 MAY 2007
566. Tagliaferri, P; Tassone, P; Blotta, S; Viscomi, C; Grillone, F; Budillon, A; Caraglia, M; Venuta, S.
Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival
pathways. CURRENT DRUG TARGETS, 6 (3): 289-300 MAY 2005
567. Tagliaferri, P; Caraglia, M; Budillon, A; Marra, M; Vitale, G; Viscomi, C; Masciari, S; Tassone,
P; Abbruzzese, A; Venuta, S. New pharmacokinetic and pharmacodynamic tools for interferon-alpha
(IFN-alpha) treatment of human cancer. CANCER IMMUNOLOGY IMMUNOTHERAPY, 54 (1): 1-10
JAN 2005
568. Taliani, G; Gemignani, G; Ferrari, C; Aceti, A; Bartolozzi, D; Blanc, PL; Capanni, M; Esperti, F;
Forte, P; Guadagnino, V; Mari, T; Marino, N; Milani, S; Pasquazzi, C; Rosina, F; Tacconi, D; Toti, M;
Zignego, AL; Messerini, L; Stroffolini, T.; Nonresponder Retreatment Grp. Pegylated interferon alfa-2b